医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

OSLO, Norway

Nordic Nanovector is pleased to announce that the Japan Patent Office (JPO) has issued patent no. 5646652 entitled “NOVEL RADIOIMMUNOCONJUGATES AND USES THEREOF.” The issued claims cover Nordic Nanovector’s proprietary radioimmunotherapy (RIT) technology, including the company`s lead product candidate Betalutin™, a new targeted agent for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL).

“This patent provides additional intellectual property protection of our proprietary technology until 2031 and is an important addition to our patent portfolio,” said Chief Executive Officer Luigi Costa. “By broadening patent coverage we are protecting commercial value for the investors in attractive markets such as Japan.”

Nordic Nanovector has earlier been granted patent protection in the two most important geographical markets for radioimmunotherapies, the USA and Europe.

About Nordic Nanovector ASA

Nordic Nanovector ASA is a privately held company established in 2009. The company is developing innovative radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other difficult to treat cancers. Nordic Nanovector intends to commercialise its product candidates through strategic alliances and partnerships with experienced oncology businesses and by establishing its own sales and marketing capabilities in selected markets. The company is based and has offices and laboratories in Oslo, Norway.

The company’s lead product candidate, Betalutin™, is a radioimmunotherapeutic that aims to prolong and improve the quality of life of people who suffer from NHL. Further information can be found at: www.nordicnanovector.com.

This information was brought to you by Cision http://news.cision.com